Biotech M&A is picking back up according to BiopharmaDiveSeptember 1, 2023 In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions.
Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market.
These deals haven’t come cheap, however, with premiums on biopharma acquisitions surpassing 100% many times in recent years. Such high prices have been due, at least in part, to the fact that biotechs were able to secure large amounts of funding from private investors and the public markets, in turn forcing potential buyers to offer up more money to lock down deals.
https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/